| For: | Wang JL, Xiang BX, Song XL, Que RM, Zuo XC, Xie YL. Prevalence of polymyxin-induced nephrotoxicity and its predictors in critically ill adult patients: A meta-analysis. World J Clin Cases 2022; 10(31): 11466-11485 [PMID: 36387815 DOI: 10.12998/wjcc.v10.i31.11466] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i31/11466.htm |
| Number | Citing Articles |
| 1 |
Tingting Liu, Jing Zhou, Xuejiao Liu, Xiaolu Xu. Comparative study of colistin methanesulfonate and colistin sulfate/polymyxin B in the treatment of ceftazidime-avibactam resistant Gram-negative bacilli infections. Intelligent Pharmacy 2024; 2(5) doi: 10.1016/j.ipha.2024.01.004
|
| 2 |
Edgars Liepinsh, Valerija Meinardte, Kristaps Krims-Davis, Stanislava Korzh, Eduards Sevostjanovs, Helena Cirule, Maija Dambrova, Francesc Rabanal. Polymyxin antibiotics induce nephrotoxicity through the selective inhibition of Complex I-dependent respiration in mouse and rat mitochondria. Archives of Toxicology 2026; doi: 10.1007/s00204-026-04566-x
|
| 3 |
Hassan Gamal, Cesar Augusto Roque-Borda, Beatriz G. de la Torre, Fernando Albericio. Structure function and design of polymyxins to enable safer and more potent anti Gram negative agents. European Journal of Medicinal Chemistry 2026; 305 doi: 10.1016/j.ejmech.2026.118575
|
| 4 |
Rachna B. Patel, Bhavin B. Patel, Nisarg R. Hajariwala, Pankaj Maheshawari, Virendra C. Chauhan, Killol Kaneria, Anil Ganju, Abhishek Kadam, Pradhya Harshe, Chinmay Sapre, Kamlesh Parikh. A series of clinical cases highlighting cardiotoxicity induced by polymyxin B. Emergency Care Journal 2025; doi: 10.4081/ecj.2025.13468
|
| 5 |
Kannan Sridharan. Nephrotoxicity risks of colistin-combination therapy: a USFDA adverse event reporting system analysis using disproportionality and interaction assessment. Expert Opinion on Drug Safety 2025; doi: 10.1080/14740338.2025.2499672
|
| 6 |
Subhash Todi, Bharat G Jagiasi, Deven Juneja, Justin A Gopaldas, Kapil D Soni, Sunil Karanth, Ritu Singh, Mohit Kharbanda, Ashutosh Bhardwaj, Tapas K Sahoo, Shilpushp Bhosale, Sharmili Sinha, Manish Bharti, Anuj M Clerk, Amit Kumar, Bram Rochwerg, Vinod K Singh, Pradip K Bhattacharya. Indian Society of Critical Care Medicine Guidelines on Evidence-based Recommendations for the Treatment of Carbapenem-resistant Enterobacterales, Carbapenem-resistant Acinetobacter baumannii, and Carbapenem-resistant Pseudomonas aeruginosa in Critically Ill Patients: A GRADE-guided Approach. Indian Journal of Critical Care Medicine 2026; 30(6) doi: 10.5005/jp-journals-10071-25216
|
| 7 |
Hannah Collings, Medi Stone, Anouska Jha, François-Xavier Houde, Florence D’Adamo, Todd Waldenberg, Emre Yücel. Safety Profiles of Polymyxins, Aminoglycosides, and Imipenem/Cilastatin/Relebactam (IMI/REL) in the Treatment of Gram-Negative Infections: A Literature Review. Antibiotics 2026; 15(5) doi: 10.3390/antibiotics15050422
|
| 8 |
Long Wen, Xuefeng Yuan, Xiaohui Liu, Dixuan Jiang, Lihua Liu, Jiheng Liu. The association between acute kidney injury and Polymyxin B treatment: A retrospective cohort study. Science Progress 2025; 108(3) doi: 10.1177/00368504251379362
|
| 9 |
Asha K. Rajan, Vijayanarayana Kunhikatta, Ravindra Prabhu Attur, Souvik Chaudhuri, Vishal Shanbhag, Girish Thunga. Clinician decision-making for polymyxin dosing in critically ill patients with renal impairment: a qualitative study. Scientific Reports 2026; 16(1) doi: 10.1038/s41598-026-55210-8
|
| 10 |
Fatma Nisa Ballı, Pınar Bakır Ekinci, Melek Kurtaran, Emre Kara, Gülçin Telli Dizman, Meliha Çağla Sönmezer, Mutlu Hayran, Kutay Demirkan, Gökhan Metan. Battle of polymyxin induced nephrotoxicity: Polymyxin B versus colistin. International Journal of Antimicrobial Agents 2024; 63(2) doi: 10.1016/j.ijantimicag.2023.107035
|
| 11 |
Vesna Šuljagić, Vojislava Nešković, Duško Maksimović, Ivo Udovičić, Danijela Đurić-Petković, Nenad Perišić, Ivan Leković, Đorđe Taušan, Bojan Rakonjac, Katarina Vasiljević, Nemanja Rančić. Antibiotic Use, Healthcare-Associated Infections, and Antimicrobial Resistance in Intensive Care Unit of a Serbian Tertiary University Hospital, 2018–2024: An Ecological Analysis. Antibiotics 2025; 14(11) doi: 10.3390/antibiotics14111110
|
| 12 |
Han Wang, Yangyang Tan. Combination of aztreonam, colistin and tigecycline in the treatment of neonatal carbapenemase-producing Enterobacteriaceae infection: a case report. BMC Pediatrics 2026; 26(1) doi: 10.1186/s12887-026-06511-4
|
| 13 |
Xiaojie Zhao, Jingwei Wang, Xinyi Deng, Mengjiao Shi, Shuang Song, Shulong Zhao, Jingfang Sun, Youzhen Ma, Wenwen Zhu, Fei Jiang, Jing Tong, Haiquan Kang. Eravacycline monotherapy and combination therapy against KPC-2- and NDM-1-co- producing Klebsiella pneumoniae: in vitro and in vivo activity analysis. Frontiers in Microbiology 2026; 17 doi: 10.3389/fmicb.2026.1802577
|
| 14 |
Wei Li, Yu Liu, Lu Xiao, Xuezhou Cai, Weixi Gao, Dong Xu, Shishi Han, Yan He. Development and validation of a prognostic nomogram to predict 30-day all-cause mortality in patients with CRO infection treated with colistin sulfate. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1409998
|
| 15 |
Camila L P A M Bezerra, Eusébio L dos Santos, Maura S Oliveira, Maria Beatriz S Dias, Anna S Levin, Maristela P Freire, Icaro Boszczowski, Matias C Salomão. Crude Mortality Associated With the Empirical Use of Polymyxins in Septic Patients in a Setting of High Prevalence of Carbapenem-Resistant Gram-negative Bacteria: Retrospective Analysis of a Cohort. Clinical Infectious Diseases 2023; 77(Supplement_1) doi: 10.1093/cid/ciad272
|
| 16 |
Qin‐jie Yang, Bi‐xiao Xiang, Mong‐hsiu Song, Chien‐yi Yang, Jun‐hao Liang, Yue‐liang Xie, Xiao‐cong Zuo. Acute kidney injury with intravenous colistin sulfate compared with polymyxin B in critically ill patients: A real‐world, retrospective cohort study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2024; 44(8) doi: 10.1002/phar.4601
|
| 17 |
Qiao-Yi Wei, Wei Shen, Zhao-Yuan Chen, Xin-Xing Chen, Feng Xu, Heng Fan. Efficacy and Safety of Different Colistin Administration Routes for Nosocomial Pneumonia Caused by Carbapenem-Resistant Organisms: A Single Centre, Open Label, Prospective Cohort Study. Drug Design, Development and Therapy 2026; doi: 10.2147/DDDT.S577270
|
| 18 |
Jingqian Su, Shun Wu, Fen Zhou, Zhiyong Tong. Research Progress of Macromolecules in the Prevention and Treatment of Sepsis. International Journal of Molecular Sciences 2023; 24(16) doi: 10.3390/ijms241613017
|
| 19 |
Pınar AYSERT-YILDIZ, Özge ÖZGEN-TOP, Ahmet Furkan ŞENTÜRK, Sait KANIK, Hasan Selçuk ÖZGER, Murat DİZBAY. Polymyxin B vs. colistin: the comparison of neurotoxic and nephrotoxic effects of the two polymyxins. BMC Infectious Diseases 2024; 24(1) doi: 10.1186/s12879-024-09759-2
|
| 20 |
Iman Karimzadeh, Sandra L. Kane-Gill, Binglei Ma. Anti-Infective-Associated AKI: A Narrative Review of the Epidemiology, Mechanisms, Risk Factors, Biomarkers, Clinical Course, Monitoring, Prevention, and Therapeutic Strategies. Antibiotics 2025; 14(11) doi: 10.3390/antibiotics14111138
|
| 21 |
Yuanbing Wu, Shanshan Jiang, Dongyang Li, Yaxue Wu, Qian Li, Xing Wang, Bin Liu, Haiyan Bao, Depei Wu, Xiaohui Hu. Clinical Efficacy and Safety of Colistin Sulfate in the Treatment of Carbapenem-Resistant Organism Infections in Patients with Hematological Diseases. Infectious Diseases and Therapy 2024; 13(1) doi: 10.1007/s40121-023-00909-8
|
| 22 |
Tuğba Yıldırım, Hüseyin Serdar Savacı. Factors affecting colistin nephrotoxicity in intensive care units. Turkish Journal of Clinics and Laboratory 2026; (1) doi: 10.18663/tjcl.1811166
|